The empirical evidence for the presence of a value premium in stock markets is overwhelming. But why does this phenomenon exist? A new white paper examines a popular explanation.
Although there is by now a consensus that a strong value premium is present in the data, the reasons why this phenomenon exists are still heavily debated. In previous research we provided strong evidence against the distress risk explanation, showing that although simple value strategies can get a large exposure to distressed stocks, this does not explain the high return of value stocks.
More risk-based explanations have been proposed in the literature, but next to that there is also a school of thought which attributes the value premium to behavioral factors. In this white paper (download below) we examine one such behavioral explanation, namely the overreaction hypothesis.
According to this hypothesis, value stocks do show lower growth rates in subsequent years, and growth stocks do show higher subsequent growth rates, but not nearly as long and to the extent needed to justify the differences in valuation assigned to them by the market.
We find that although overreaction indicators appear to be fairly promising on a stand-alone basis, they are not really effective for enhancing a generic value strategy. Moreover, if we disentangle the contribution to return of various factors, valuation is significant while the overreaction indicators are not.
This indicates that valuation ratios are really driving differences in future stock returns. Based on these findings we conclude that the empirical support for the overreaction hypothesis is quite weak.
This report is not available for users from countries where the offering of foreign financial services is not permitted, such as US Persons.
Your details are not shared with third parties. This information is exclusively intended for professional investors. All requests are checked.
The information contained on these pages is for marketing purposes and solely intended for Qualified Investors in accordance with the Swiss Collective Investment Schemes Act of 23 June 2006 (“CISA”) domiciled in Switzerland, Professional Clients in accordance with Annex II of the Markets in Financial Instruments Directive II (“MiFID II”) domiciled in the European Union und European Economic Area with a license to distribute / promote financial instruments in such capacity or herewith requesting respective information on products and services in their capacity as Professional Clients.
The Funds are domiciled in Luxembourg and The Netherlands. ACOLIN Fund Services AG, postal address: Affolternstrasse 56, 8050 Zürich, acts as the Swiss representative of the Fund(s). UBS Switzerland AG, Bahnhofstrasse 45, 8001 Zurich, postal address: Europastrasse 2, P.O. Box, CH-8152 Opfikon, acts as the Swiss paying agent. The prospectus, the Key Investor Information Documents (KIIDs), the articles of association, the annual and semi-annual reports of the Fund(s) may be obtained, on simple request and free of charge, at the office of the Swiss representative ACOLIN Fund Services AG. The prospectuses are also available via the website www.robeco.ch. Some funds about which information is shown on these pages may fall outside the scope of the Swiss Collective Investment Schemes Act of 26 June 2006 (“CISA”) and therefore do not (need to) have a license from or registration with the Swiss Financial Market Supervisory Authority (FINMA).
Some funds about which information is shown on this website may not be available in your domicile country. Please check the registration status in your respective domicile country. To view the RobecoSwitzerland Ltd. products that are registered/available in your country, please go to the respective Fund Selector, which can be found on this website and select your country of domicile.
Neither information nor any opinion expressed on this website constitutes a solicitation, an offer or a recommendation to buy, sell or dispose of any investment, to engage in any other transaction or to provide any investment advice or service. An investment in a Robeco Switzerland Ltd. product should only be made after reading the related legal documents such as management regulations, prospectuses, annual and semi-annual reports.